Click for best price
Hematological gnancy Drugs Market Size, Share 2022
This report contains market size and forecasts of Hematological Malignancy Drugs in Global, including the following market information:
Global Hematological Malignancy Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hematological Malignancy Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Monoclonal Antibody Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hematological Malignancy Drugs include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer and Amgen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hematological Malignancy Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hematological Malignancy Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hematological Malignancy Drugs Market Segment Percentages, by Type, 2021 (%)
Monoclonal Antibody
Immunomodulatory Drug
Tyrosine Kinase Inhibitor
Proteasome Inhibitors
Others
Global Hematological Malignancy Drugs Market, by Indication, 2017-2022, 2023-2028 ($ millions)
Global Hematological Malignancy Drugs Market Segment Percentages, by Indication, 2021 (%)
ALL
CLL
AML
NHL
DLBCL
MM
Others
Global Hematological Malignancy Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hematological Malignancy Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hematological Malignancy Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hematological Malignancy Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Sanofi
Bayer
Biogen Idec
| Report Attributes |
Report Details |
| Report Title |
Hematological Malignancy Drugs Market, Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
104 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Hematological Malignancy Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Indication
1.3 Global Hematological Malignancy Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hematological Malignancy Drugs Overall Market Size
2.1 Global Hematological Malignancy Drugs Market Size: 2021 VS 2028
2.2 Global Hematological Malignancy Drugs Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hematological Malignancy Drugs Players in Global Market
3.2 Top Global Hematological Malignancy Drugs Companies Ranked by Revenue
3.3 Global Hematological Malignancy Drugs Revenue by Companies
3.4 Top 3 and Top 5 Hematological Malignancy Drugs Companies in Global Market, by Revenue in 2021
3.5 Global Companies Hematological Malignancy Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hematological Malignancy Drugs Players in Global Market
3.6.1 List of Global Tier 1 Hematological Malignancy Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Hematological Malignancy Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Hematological Malignancy Drugs Market Size Markets, 2021 & 2028
4.1.2 Monoclonal Antibody
4.1.3 Immunomodulatory Drug
4.1.4 Tyrosine Kinase Inhibitor
4.1.5 Proteasome Inhibitors
4.1.6 Others
4.2 By Type - Global Hematological Malignancy Drugs Revenue & Forecasts
4.2.1 By Type - Global Hematological Malignancy Drugs Revenue, 2017-2022
4.2.2 By Type - Global Hematological Malignancy Drugs Revenue, 2023-2028
4.2.3 By Type - Global Hematological Malignancy Drugs Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hematological Malignancy Drugs Market Size, 2021 & 2028
5.1.2 ALL
5.1.3 CLL
5.1.4 AML
5.1.5 NHL
5.1.6 DLBCL
5.1.7 MM
5.1.8 Others
5.2 By Indication - Global Hematological Malignancy Drugs Revenue & Forecasts
5.2.1 By Indication - Global Hematological Malignancy Drugs Revenue, 2017-2022
5.2.2 By Indication - Global Hematological Malignancy Drugs Revenue, 2023-2028
5.2.3 By Indication - Global Hematological Malignancy Drugs Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Hematological Malignancy Drugs Market Size, 2021 & 2028
6.2 By Region - Global Hematological Malignancy Drugs Revenue & Forecasts
6.2.1 By Region - Global Hematological Malignancy Drugs Revenue, 2017-2022
6.2.2 By Region - Global Hematological Malignancy Drugs Revenue, 2023-2028
6.2.3 By Region - Global Hematological Malignancy Drugs Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Hematological Malignancy Drugs Revenue, 2017-2028
6.3.2 US Hematological Malignancy Drugs Market Size, 2017-2028
6.3.3 Canada Hematological Malignancy Drugs Market Size, 2017-2028
6.3.4 Mexico Hematological Malignancy Drugs Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Hematological Malignancy Drugs Revenue, 2017-2028
6.4.2 Germany Hematological Malignancy Drugs Market Size, 2017-2028
6.4.3 France Hematological Malignancy Drugs Market Size, 2017-2028
6.4.4 U.K. Hematological Malignancy Drugs Market Size, 2017-2028
6.4.5 Italy Hematological Malignancy Drugs Market Size, 2017-2028
6.4.6 Russia Hematological Malignancy Drugs Market Size, 2017-2028
6.4.7 Nordic Countries Hematological Malignancy Drugs Market Size, 2017-2028
6.4.8 Benelux Hematological Malignancy Drugs Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Hematological Malignancy Drugs Revenue, 2017-2028
6.5.2 China Hematological Malignancy Drugs Market Size, 2017-2028
6.5.3 Japan Hematological Malignancy Drugs Market Size, 2017-2028
6.5.4 South Korea Hematological Malignancy Drugs Market Size, 2017-2028
6.5.5 Southeast Asia Hematological Malignancy Drugs Market Size, 2017-2028
6.5.6 India Hematological Malignancy Drugs Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Hematological Malignancy Drugs Revenue, 2017-2028
6.6.2 Brazil Hematological Malignancy Drugs Market Size, 2017-2028
6.6.3 Argentina Hematological Malignancy Drugs Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Hematological Malignancy Drugs Revenue, 2017-2028
6.7.2 Turkey Hematological Malignancy Drugs Market Size, 2017-2028
6.7.3 Israel Hematological Malignancy Drugs Market Size, 2017-2028
6.7.4 Saudi Arabia Hematological Malignancy Drugs Market Size, 2017-2028
6.7.5 UAE Hematological Malignancy Drugs Market Size, 2017-2028
7 Players Profiles
7.1 Roche
7.1.1 Roche Corporate Summary
7.1.2 Roche Business Overview
7.1.3 Roche Hematological Malignancy Drugs Major Product Offerings
7.1.4 Roche Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.1.5 Roche Key News
7.2 Celgene
7.2.1 Celgene Corporate Summary
7.2.2 Celgene Business Overview
7.2.3 Celgene Hematological Malignancy Drugs Major Product Offerings
7.2.4 Celgene Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.2.5 Celgene Key News
7.3 Novartis
7.3.1 Novartis Corporate Summary
7.3.2 Novartis Business Overview
7.3.3 Novartis Hematological Malignancy Drugs Major Product Offerings
7.3.4 Novartis Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.3.5 Novartis Key News
7.4 Bristol-Myers Squibb
7.4.1 Bristol-Myers Squibb Corporate Summary
7.4.2 Bristol-Myers Squibb Business Overview
7.4.3 Bristol-Myers Squibb Hematological Malignancy Drugs Major Product Offerings
7.4.4 Bristol-Myers Squibb Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.4.5 Bristol-Myers Squibb Key News
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Corporate Summary
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Hematological Malignancy Drugs Major Product Offerings
7.5.4 Johnson & Johnson Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.5.5 Johnson & Johnson Key News
7.6 Merck & Co.
7.6.1 Merck & Co. Corporate Summary
7.6.2 Merck & Co. Business Overview
7.6.3 Merck & Co. Hematological Malignancy Drugs Major Product Offerings
7.6.4 Merck & Co. Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.6.5 Merck & Co. Key News
7.7 AstraZeneca
7.7.1 AstraZeneca Corporate Summary
7.7.2 AstraZeneca Business Overview
7.7.3 AstraZeneca Hematological Malignancy Drugs Major Product Offerings
7.7.4 AstraZeneca Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.7.5 AstraZeneca Key News
7.8 Pfizer
7.8.1 Pfizer Corporate Summary
7.8.2 Pfizer Business Overview
7.8.3 Pfizer Hematological Malignancy Drugs Major Product Offerings
7.8.4 Pfizer Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.8.5 Pfizer Key News
7.9 Amgen
7.9.1 Amgen Corporate Summary
7.9.2 Amgen Business Overview
7.9.3 Amgen Hematological Malignancy Drugs Major Product Offerings
7.9.4 Amgen Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.9.5 Amgen Key News
7.10 Eli Lilly
7.10.1 Eli Lilly Corporate Summary
7.10.2 Eli Lilly Business Overview
7.10.3 Eli Lilly Hematological Malignancy Drugs Major Product Offerings
7.10.4 Eli Lilly Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.10.5 Eli Lilly Key News
7.11 AbbVie
7.11.1 AbbVie Corporate Summary
7.11.2 AbbVie Business Overview
7.11.3 AbbVie Hematological Malignancy Drugs Major Product Offerings
7.11.4 AbbVie Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.11.5 AbbVie Key News
7.12 Takeda
7.12.1 Takeda Corporate Summary
7.12.2 Takeda Business Overview
7.12.3 Takeda Hematological Malignancy Drugs Major Product Offerings
7.12.4 Takeda Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.12.5 Takeda Key News
7.13 Sanofi
7.13.1 Sanofi Corporate Summary
7.13.2 Sanofi Business Overview
7.13.3 Sanofi Hematological Malignancy Drugs Major Product Offerings
7.13.4 Sanofi Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.13.5 Sanofi Key News
7.14 Bayer
7.14.1 Bayer Corporate Summary
7.14.2 Bayer Business Overview
7.14.3 Bayer Hematological Malignancy Drugs Major Product Offerings
7.14.4 Bayer Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.14.5 Bayer Key News
7.15 Biogen Idec
7.15.1 Biogen Idec Corporate Summary
7.15.2 Biogen Idec Business Overview
7.15.3 Biogen Idec Hematological Malignancy Drugs Major Product Offerings
7.15.4 Biogen Idec Hematological Malignancy Drugs Revenue in Global Market (2017-2022)
7.15.5 Biogen Idec Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Hematological Malignancy Drugs Market Opportunities & Trends in Global Market
Table 2. Hematological Malignancy Drugs Market Drivers in Global Market
Table 3. Hematological Malignancy Drugs Market Restraints in Global Market
Table 4. Key Players of Hematological Malignancy Drugs in Global Market
Table 5. Top Hematological Malignancy Drugs Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Hematological Malignancy Drugs Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Hematological Malignancy Drugs Revenue Share by Companies, 2017-2022
Table 8. Global Companies Hematological Malignancy Drugs Product Type
Table 9. List of Global Tier 1 Hematological Malignancy Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hematological Malignancy Drugs Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Hematological Malignancy Drugs Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Hematological Malignancy Drugs Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Hematological Malignancy Drugs Revenue in Global (US$, Mn), 2023-2028
Table 14. By Indication ? Global Hematological Malignancy Drugs Revenue, (US$, Mn), 2021 & 2028
Table 15. By Indication - Hematological Malignancy Drugs Revenue in Global (US$, Mn), 2017-2022
Table 16. By Indication - Hematological Malignancy Drugs Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Hematological Malignancy Drugs Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Hematological Malignancy Drugs Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Hematological Malignancy Drugs Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Hematological Malignancy Drugs Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Hematological Malignancy Drugs Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Hematological Malignancy Drugs Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Hematological Malignancy Drugs Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Hematological Malignancy Drugs Revenue, (US$, Mn), 2023-2028
Table 30. Roche Corporate Summary
Table 31. Roche Hematological Malignancy Drugs Product Offerings
Table 32. Roche Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 33. Celgene Corporate Summary
Table 34. Celgene Hematological Malignancy Drugs Product Offerings
Table 35. Celgene Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 36. Novartis Corporate Summary
Table 37. Novartis Hematological Malignancy Drugs Product Offerings
Table 38. Novartis Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 39. Bristol-Myers Squibb Corporate Summary
Table 40. Bristol-Myers Squibb Hematological Malignancy Drugs Product Offerings
Table 41. Bristol-Myers Squibb Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 42. Johnson & Johnson Corporate Summary
Table 43. Johnson & Johnson Hematological Malignancy Drugs Product Offerings
Table 44. Johnson & Johnson Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 45. Merck & Co. Corporate Summary
Table 46. Merck & Co. Hematological Malignancy Drugs Product Offerings
Table 47. Merck & Co. Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 48. AstraZeneca Corporate Summary
Table 49. AstraZeneca Hematological Malignancy Drugs Product Offerings
Table 50. AstraZeneca Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 51. Pfizer Corporate Summary
Table 52. Pfizer Hematological Malignancy Drugs Product Offerings
Table 53. Pfizer Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 54. Amgen Corporate Summary
Table 55. Amgen Hematological Malignancy Drugs Product Offerings
Table 56. Amgen Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 57. Eli Lilly Corporate Summary
Table 58. Eli Lilly Hematological Malignancy Drugs Product Offerings
Table 59. Eli Lilly Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 60. AbbVie Corporate Summary
Table 61. AbbVie Hematological Malignancy Drugs Product Offerings
Table 62. AbbVie Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 63. Takeda Corporate Summary
Table 64. Takeda Hematological Malignancy Drugs Product Offerings
Table 65. Takeda Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 66. Sanofi Corporate Summary
Table 67. Sanofi Hematological Malignancy Drugs Product Offerings
Table 68. Sanofi Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 69. Bayer Corporate Summary
Table 70. Bayer Hematological Malignancy Drugs Product Offerings
Table 71. Bayer Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
Table 72. Biogen Idec Corporate Summary
Table 73. Biogen Idec Hematological Malignancy Drugs Product Offerings
Table 74. Biogen Idec Hematological Malignancy Drugs Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Hematological Malignancy Drugs Segment by Type in 2021
Figure 2. Hematological Malignancy Drugs Segment by Indication in 2021
Figure 3. Global Hematological Malignancy Drugs Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Hematological Malignancy Drugs Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Hematological Malignancy Drugs Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hematological Malignancy Drugs Revenue in 2021
Figure 8. By Type - Global Hematological Malignancy Drugs Revenue Market Share, 2017-2028
Figure 9. By Indication - Global Hematological Malignancy Drugs Revenue Market Share, 2017-2028
Figure 10. By Region - Global Hematological Malignancy Drugs Revenue Market Share, 2017-2028
Figure 11. By Country - North America Hematological Malignancy Drugs Revenue Market Share, 2017-2028
Figure 12. US Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Hematological Malignancy Drugs Revenue Market Share, 2017-2028
Figure 16. Germany Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 17. France Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Hematological Malignancy Drugs Revenue Market Share, 2017-2028
Figure 24. China Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 28. India Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Hematological Malignancy Drugs Revenue Market Share, 2017-2028
Figure 30. Brazil Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Hematological Malignancy Drugs Revenue Market Share, 2017-2028
Figure 33. Turkey Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Hematological Malignancy Drugs Revenue, (US$, Mn), 2017-2028
Figure 37. Roche Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Celgene Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Novartis Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bristol-Myers Squibb Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Johnson & Johnson Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Merck & Co. Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. AstraZeneca Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Pfizer Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Amgen Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Eli Lilly Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. AbbVie Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Takeda Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Sanofi Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Bayer Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Biogen Idec Hematological Malignancy Drugs Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
